CJC-1295 and ipamorelin: three molecules, two names, and which papers describe what

This is the most reliably confused pair of compounds in the research-peptide market. The name "CJC-1295" is used for two different molecules whose published literatures barely overlap, and ipamorelin is routinely discussed as though it did the same job by a slightly different route, when it acts on a different receptor.

Getting that straight is the point of the page. Everything else is downstream of knowing which molecule a given paper studied.

Three molecules

The first two are growth hormone-releasing hormone analogues and act at the GHRH receptor on the anterior pituitary. The third does not. It acts at the growth hormone secretagogue receptor — the ghrelin receptor — which is a separate receptor on the same cells.

The DAC is the whole difference between the first two. ConjuChem attached a reactive linker to the peptide so that, in circulation, it forms a covalent bond with a cysteine residue on serum albumin. The peptide then travels as part of a large, long-lived carrier protein instead of being cleared in minutes. That bioconjugate approach, and the identification of CJC-1295 as the resulting long-acting analogue, is what the originating paper describes (PMID 15817669).

Remove the linker and the entire pharmacokinetic rationale goes with it. What remains is a stabilised GRF(1-29) fragment with a half-life in the same range as the natural hormone's — a reasonable research compound, but not the molecule ConjuChem took into trials.

What the CJC-1295 trial literature actually covers

There is human data here, and it is worth being precise about its subject.

Teichman and colleagues gave CJC-1295 — the DAC version — to healthy adults and followed growth hormone and IGF-I, reporting sustained elevation after single and repeated administration, over a period long enough to distinguish it from a short-acting GHRH analogue (PMID 16352683). Ionescu and Frohman then took up the obvious objection: continuous stimulation of a receptor that normally sees pulses might abolish pulsatility. They reported that pulsatile secretion persisted (PMID 17018654).

Those are the two papers most often cited in marketing copy for material sold as "CJC-1295", and in nearly every case the material being sold is the no-DAC version. The papers do not describe it. A half-life of days and a half-life of thirty minutes are not variations of one pharmacology; they are the difference between continuous receptor occupancy and a transient pulse, which is precisely what the second paper was investigating.

ConjuChem's programme did not continue to registration. CJC-1295 is approved nowhere — not by Health Canada, not by the FDA, not by the EMA — in either form.

For contrast, the GHRH analogue that did complete a registration programme is tesamorelin, approved as Egrifta for one indication in one population. The tesamorelin guide sets out what that approval does and does not transfer to research material.

What the ipamorelin literature covers

Ipamorelin came out of Novo Nordisk and was characterised by Raun and colleagues as the first selective growth hormone secretagogue (PMID 9849822). The selectivity claim is the substance of it. Earlier ghrelin-receptor agonists released growth hormone but also raised ACTH, cortisol and prolactin; ipamorelin was reported to release growth hormone with much less of that collateral endocrine activity. That is why it is discussed differently from the GHRPs that preceded it.

Pharmacokinetic and pharmacodynamic modelling in human volunteers followed (PMID 10496658), so there is a small human dataset for the compound itself.

Its clinical development then went somewhere unexpected. Because ghrelin-receptor agonism affects gastric motility, ipamorelin was investigated for postoperative ileus — the stalling of gut function after abdominal surgery. There is a rodent model (PMID 19289567) and a randomised proof-of-concept study in patients undergoing bowel resection (PMID 25331030). That programme did not proceed to approval either, and ipamorelin is approved nowhere.

What is thin, for a compound with this much name recognition, is long-term human data in anything resembling the context it is marketed for. Ipamorelin and somatopause covers that gap.

The blend, and what can be said about it

This shop sells the two compounds together, as a CJC-1295 / Ipamorelin blend, and the honest position on it is short.

The stated rationale is that the two act at different receptors on the same pituitary somatotrophs, so a GHRH-receptor agonist and a ghrelin-receptor agonist might combine differently from either alone. That is a coherent hypothesis with a basis in the separate pharmacologies. It is not a finding. No published literature examines this combination, in any species, and results for either component separately do not transfer to a mixture.

A blend also raises an analytical question a single compound does not: a certificate has to establish two identities and a ratio, not one purity figure, and a two-component product tested as though it were one is undertested. The general argument is in what a certificate of analysis establishes.

Supplied here as the CJC-1295 / Ipamorelin blend and as single-compound Ipamorelin. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. Nothing here is medical, dosing, or therapeutic guidance.

Where the evidence stops

Neither compound is approved anywhere, for anything. Both are research material. Both sit on the World Anti-Doping Agency's prohibited list — GHRH analogues and growth hormone secretagogues are separately named categories on it — which matters to anyone who competes at any level.

The human data is short-term and small. A handful of studies in healthy volunteers, plus one surgical-recovery programme for ipamorelin that stopped. Nothing establishes what either compound does over long periods.

Growth hormone secretion is an endpoint, not a result. Every paper above measures hormone release or its downstream marker. What follows from a change in that marker is a separate question these papers do not address.

The sequence you buy may not be the sequence in the paper. This is the practical consequence of everything above: material sold under the CJC-1295 name is usually the no-DAC version, and the trial literature is about the DAC version. Ask which one a vial contains, and expect a mass-spectrometric answer rather than a verbal one.

Common questions

Is CJC-1295 without DAC just a weaker CJC-1295? No. It is a different molecule with a different duration of action and essentially a different mechanism of exposure — a transient pulse rather than continuous receptor occupancy. The DAC version's clinical pharmacology was built entirely on its albumin binding, and nothing in that data carries over.

Why combine a GHRH analogue with a ghrelin-receptor agonist? The reasoning is that they are two different receptors on the same cell. It is a plausible hypothesis for a research question. There is no published study of the combination, so there is no result to report, and anyone claiming one is describing an expectation.

Is ipamorelin safer because it is selective? "Selective" is a statement about receptor and hormone specificity, not about safety. Raun's work reported less ACTH, cortisol and prolactin release than earlier secretagogues — a pharmacological finding in a controlled setting. A safety conclusion would require long-term human data, which does not exist.

Can I buy these in Canada? They are sold as research chemicals for laboratory use only. Neither is an approved drug in Canada and neither is sold for human use.

Selected Research References

1. Jetté L, Léger R, Thibaudeau K, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005;146(7):3052-3058. pubmed.ncbi.nlm.nih.gov/15817669
2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. pubmed.ncbi.nlm.nih.gov/16352683
3. Ionescu M, Frohman LA. Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797. pubmed.ncbi.nlm.nih.gov/17018654
4. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. pubmed.ncbi.nlm.nih.gov/9849822
5. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. pubmed.ncbi.nlm.nih.gov/10496658
6. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, in a Rodent Model of Postoperative Ileus. Journal of Pharmacology and Experimental Therapeutics. 2009;329(3):1110-1116. pubmed.ncbi.nlm.nih.gov/19289567
7. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, Randomized, Controlled, Proof-of-Concept Study of the Ghrelin Mimetic Ipamorelin for the Management of Postoperative Ileus in Bowel Resection Patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. pubmed.ncbi.nlm.nih.gov/25331030

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.